Grifols (GIFLF) Non-cash Items (2010 - 2016)
Grifols' (GIFLF) quarterly Non-cash Items came in at $108.1 million in Q4 2016, down 18.04% on a YoY basis from $131.9 million in Q1 2016, and up 9.57% quarter-over-quarter from $98.7 million in Q3 2016.
Analysis
Grifols (GIFLF) Non-cash Items (2010 - 2016) Analysis & Trends
Grifols (GIFLF) has reported Non-cash Items for 7 consecutive years, with $108.1 million the latest figure, recorded in Q4 2016.
- For the quarter ending Q4 2016, Non-cash Items fell 18.04% year-over-year to $108.1 million; the trailing twelve-month figure through Dec 2016 stood at $480.1 million (down 6.07% YoY), and the FY2025 full-year result was $1.3 billion, up 2.69% from the prior year.
- Non-cash Items improved to $108.1 million in Q4 2016 per GIFLF's latest filing, from $98.7 million in the prior quarter.
- Across five years, Non-cash Items topped out at $511.6 million in Q3 2014 and bottomed at -$156.6 million in Q2 2014.
- Historically, Non-cash Items has averaged $130.6 million across 5 years, with a median of $122.3 million in 2012.
- The sharpest annual moves came in 2012 and 2014: Non-cash Items surged 556.04% in 2012, then tumbled 236.46% in 2014.
- Over 5 years, Non-cash Items stood at $150.9 million in 2012, then decreased by 29.88% to $105.8 million in 2013, then jumped by 36.46% to $144.4 million in 2014, then dropped by 8.64% to $131.9 million in 2015, then decreased by 18.04% to $108.1 million in 2016.
- According to Business Quant data, Non-cash Items over the past three periods registered $108.1 million, $98.7 million, and $131.9 million for Q4 2016, Q3 2016, and Q4 2015 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 108.12 Mn |
| Sep 30, 2016 | 98.68 Mn |
| Dec 31, 2015 | 131.92 Mn |
| Sep 30, 2015 | 141.38 Mn |
| Jun 30, 2015 | 131.67 Mn |
| Mar 31, 2015 | 106.15 Mn |
| Dec 31, 2014 | 144.40 Mn |
| Sep 30, 2014 | 511.64 Mn |
| Jun 30, 2014 | -156.60 Mn |
| Mar 31, 2014 | 156.73 Mn |
| Dec 31, 2013 | 105.82 Mn |
| Sep 30, 2013 | 109.37 Mn |
| Jun 30, 2013 | 114.76 Mn |
| Mar 31, 2013 | 131.61 Mn |
| Dec 31, 2012 | 150.91 Mn |
| Sep 30, 2012 | 120.17 Mn |
| Jun 30, 2012 | 120.92 Mn |
| Mar 31, 2012 | 123.78 Mn |
| Dec 31, 2011 | 188.03 Mn |
| Sep 30, 2011 | 115.66 Mn |